{"id":"ocrelizumab-sc","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Infusion-related reactions"},{"rate":"10-20%","effect":"Infections"},{"rate":"10-20%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL2108041","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to CD20, ocrelizumab SC induces direct and indirect mechanisms of action that lead to the depletion of B cells, which play a key role in the pathogenesis of multiple sclerosis and non-Hodgkin's lymphoma.","oneSentence":"Ocrelizumab SC is a monoclonal antibody that targets CD20 on B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:33.190Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"},{"name":"Primary progressive multiple sclerosis"},{"name":"Non-Hodgkin's lymphoma"}]},"trialDetails":[{"nctId":"NCT06780150","phase":"","title":"A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-09-26","conditions":"Multiple Sclerosis","enrollment":842},{"nctId":"NCT06675955","phase":"PHASE3","title":"An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-12-13","conditions":"Multiple Sclerosis","enrollment":500},{"nctId":"NCT07074886","phase":"PHASE2","title":"A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-11-13","conditions":"Multiple Sclerosis","enrollment":182},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT06668324","phase":"","title":"Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-11-15","conditions":"Multiple Sclerosis","enrollment":134},{"nctId":"NCT05232825","phase":"PHASE3","title":"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-05-03","conditions":"Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis","enrollment":236},{"nctId":"NCT03972306","phase":"PHASE1","title":"A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-08-12","conditions":"Multiple Sclerosis (MS)","enrollment":134},{"nctId":"NCT03477500","phase":"PHASE3","title":"Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2018-03-21","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT06127095","phase":"","title":"A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments","status":"COMPLETED","sponsor":"Biogen","startDate":"2023-11-24","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":474},{"nctId":"NCT06711354","phase":"","title":"B-cell Depletion in Offspring to Women With MS Under Immunomodulatory Treatment","status":"NOT_YET_RECRUITING","sponsor":"Region Stockholm","startDate":"2025-06","conditions":"Multiple Sclerosis, B-Cell Deficiency, Offspring, Adult","enrollment":111},{"nctId":"NCT02545868","phase":"PHASE3","title":"A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-10-27","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":102},{"nctId":"NCT01412333","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09-20","conditions":"Relapsing Multiple Sclerosis","enrollment":835},{"nctId":"NCT01247324","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-08-31","conditions":"Relapsing Multiple Sclerosis","enrollment":821},{"nctId":"NCT04448977","phase":"","title":"Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI","status":"UNKNOWN","sponsor":"Kessler Foundation","startDate":"2021-05-06","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":60},{"nctId":"NCT04767698","phase":"PHASE2","title":"Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2021-10-01","conditions":"Multiple Sclerosis","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RO4964913"],"phase":"phase_3","status":"active","brandName":"Ocrelizumab SC","genericName":"Ocrelizumab SC","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ocrelizumab SC is a monoclonal antibody that targets CD20 on B cells. Used for Relapsing forms of multiple sclerosis, Primary progressive multiple sclerosis, Non-Hodgkin's lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}